Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Colorectal Neoplasms 25Pancreatic Neoplasms 21Neoplasm Metastasis 17Neuroblastoma 8Rhabdomyosarcoma 6Lung Neoplasms 6Colonic Neoplasms 6Rectal Neoplasms 5Neoplasms 5Esophageal Squamous Cell Carcinoma 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma, Ewing 4Sarcoma 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Biliary Tract Neoplasms 3Wilms Tumor 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Kidney Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

peginterferon alfa-2b 1liposomal doxorubicin 1dolutegravir 1belinostat 1Zidovudine 1Tenofovir 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Introns 1Gemcitabine 1Doxorubicin 1Cyclophosphamide 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia-Lymphoma, Adult T-Cell × Irinotecan × 90 days × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡